PTO/SB/08b (04-09)
Approved for use through 05/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/785,497
Filing Date	February 24, 2004
First Named Inventor	Mark W. Becker et al.
Art Unit	1657
Examiner Name	P.C. Martin
Attorney Docket Number	249.P2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,591,851	01-07-1997	Alexander	
	AB*	US-5,656,745	08-12-1997	Bischofberger et al.	
	AC*	US-5,717,095	02-10-1998	Armilli et al.	
	AD*	US-5,756,486	05-26-1998	Alexander et al.	
	AE*	US-5,886,179	03-23-1999	Arimilli et al.	
	AF*	US-6,225,460	05-01-2001	Bischofberger et al.	
	AG*	US-7,390,791	06-24-2008	Becker et al.	
	AH*	US-20020119443	08-29-2002	Becker et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	BA	WO-0208241	01-31-2002	Gilead Sciences Inc et al.		
	BB	WO-9200988	01-23-1992	Bodor Nicholas S		

Examiner Signature	/Paul Martin/	Date Considered	07/20/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] CITE NO.: Those applications(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. [2] Applicant's unique citation designation number (optional). [3] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [4] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [5] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [6] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./

PTO/SB/08b (04-09)
Approved for use through 05/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 2

Complete if Known	
Application Number	10/785,497
Filing Date	February 24, 2004
First Named Inventor	Mark W. Becker et al.
Art Unit	1657
Examiner Name	P.C. Martin
Attorney Docket Number	249.P2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Beach et al. (1998) "Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions," *Clinical Thereapeutics* 20(1):2-25	
	CB	CAMP, N.P. et al. (1995) "Synthesis of Peptide Analogues Containing Phosphonamidate Methyl Ester Functionality: HIV-1 Proteinase Inhibitors Possessing Unique Cell Uptake Properties," Bioorganic & Medicinal Chemistry 3(3):297-312	
	CC	Cihlar et al. (2006) "Suppression of HIV-1 Protease Inhibitor Resistance by Phosphonate-mediated solvent anchoring," *Journal of Molecular Biology* 363(3):635-647	
	CD	Eddershaw et al. (2000) "ADME/PK as part of a retional approach to drug discovery" *Drug Discovery Today* 5(9):409-414	
	CE	FRANCHETTI, P., et al. (1998) "Potent and Selective Inhibitors of Human Immunodeficiency Virus Protease Structurally Related to L-94,746," *Antiviral Chemistry & Chemotherapy* 9(4):303-309	
	CF	GULICK (2003) "New Antiviral Drugs," *Clinical Microbiology amd Infectious Diseases* 9:186-193	
	CG	HOLY (2003) "Phosphonomethoxyalkyl Analogs of Nucleotides," *Current Pharmaceutical Design* 9:2567-2592	
	CH	Hoggard et al. (2002) "Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules," *Current Opinion in Infectious Diseases* 15(1):3-8	
	CI	Kiso et al. (1999) "Design of smalll peptidominetic HIV-1 Protease Inhibitors and Prodrug Forms,," 6(5/6):275-281	
	CJ	Krise et al. (1996) "Prodrugs of Phosphates, Phosphanates, and Phosphinates," *Advanced Drug Delivery Reviews* 19(2):287-310	
	CK	Kubota et al. (1998) "Novel inhibitory effects of gamma-glutamylcysteine ethyl ester against human immunodeficiency virus type 1 production and propagation," *Antimicrobial Agents and Chemotherapy* 42(5):1200-1206	
	CL	Lee et al.(2002) 'In Vivo and In Vitro Characterization of GS 7340, an isopropylalaninyl phnyl ester prodrug of Tenofovir: selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. *9th Conference of Retroviruses and Opporunistic infectioons, Abstract No. 384T*	
	CM	Robbins et al. (1998) "Anti-Human Immunodeficiney Virus Activity and Cellular Metabolism of A Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl) Adenine (PMPA), Bis(Isopropyloxymethylcarbonyl) PMPA" *Antimicrobial Agents and Chemotherapy* 42(3):612-617	
	CN	Zimra et al. (2000) "Uptake of pivaloyloxymethyl butyrate into leukemic esterase-catalyzed hydrolysis," *Journal of Cancer Research and Clinical Oncology* 126(12):693-698	

Examiner Signature	/Paul Martin/	Date Considered	07/20/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO : Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./